Skip to Main Content

A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma

Conditions

Other Urinary

Phase II

What is the purpose of this trial?

The study will evaluate the clinical activity of nivolumab in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.

  • Trial with
    Mirati Therapeutics
  • Start Date
    02/23/2020
  • End Date
    01/30/2021
Trial Image

For more information about this study, contact:

Matthew Piscatelli

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/23/2020
  • Study HIC
    #2000024557